Across TCGA pan-cancer cohorts, SLC2A10 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC2A10 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SLC2A10 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC2A10 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where SLC2A10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.481	0.896	<.001	31	view →
HNSC	DFS	Median	All	0.972	0.785	.014	10	view →
LUAD	OS	Median	II,III,IV	0.893	0.337	.006	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SLC2A10 tumor-vs-normal RNA expression · all SLC2A10 data types